Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancer.

Autor: Akamatsu H; Internal Medicine III, Wakayama Medical University, Wakayama, Japan., Koh Y; Internal Medicine III, Wakayama Medical University, Wakayama, Japan; Center for Biomedical Sciences, CIMS, Wakayama Medical University, Wakayama, Japan., Nishio M; Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Goto Y; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan., Hayashi H; Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan., Miura S; Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan., Tamada K; Department of Immunology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan., Kagamu H; Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan., Gemma A; Department of Pulmonary Medicine and Oncology, Nippon Medical School, Graduate School of Medicine, Tokyo, Japan., Yoshino I; Department of General Thoracic Surgery, Chiba University Graduate School of Medicine, Chiba, Japan., Misumi T; Department of Biostatistics, Yokohama City University School of Medicine, Kanagawa, Japan., Mouri A; Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan., Saito R; Department of Respiratory Medicine, Tohoku University Hospital, Miyagi, Japan., Takase N; Department of Medical Oncology, Takarazuka City Hospital, Hyogo, Japan., Yanagitani N; Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Nokihara H; Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan., Seike M; Department of Pulmonary Medicine and Oncology, Nippon Medical School, Graduate School of Medicine, Tokyo, Japan., Takamura K; Department of Respiratory Medicine, Obihiro-Kosei General Hospital, Hokkaido, Japan., Mori M; Department of Thoracic Oncology, NHO Osaka Toneyama Medical Center, Osaka, Japan., Iwasawa S; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan., Nakagawa S; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan., Mitsudomi T; Kindai Hospital Global Research Alliance Center and Thoracic Surgery, Kindai University, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan. Electronic address: mitsudom@med.kindai.ac.jp.

Publikováno v: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2024 Nov 09; Vol. 198, pp. 108017. Date of Electronic Publication: 2024 Nov 09.

Sustained Clinical Complete Response after Discontinuation of Trastuzumab-deruxetecan Due to Interstitial Pneumonia for HER2-positive Gastric adenocarcinoma with Enteroblastic Differentiation (GAED): A Case Report.

Autor: Suzuki N; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan., Odawara N; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan., Fujisawa G; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan., Ishibashi R; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan., Hata M; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan., Oya Y; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan., Tamada K; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan., Hayashi T; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan., Abe S; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan., Miyakawa Y; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan., Hayakawa Y; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan., Shinozaki-Ushiku A; Department of Pathology, The University of Tokyo Hospital, Japan., Ushiku T; Department of Pathology, The University of Tokyo Hospital, Japan., Boku N; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.; Department of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, University of Tokyo, Japan., Fujishiro M; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.

Publikováno v: Internal medicine (Tokyo, Japan) [Intern Med] 2024 Jun 06. Date of Electronic Publication: 2024 Jun 06.

Phase I study of a novel therapeutic vaccine as perioperative treatment for patients with surgically resectable hepatocellular carcinoma: The YCP02 trial.

Autor: Nakajima M; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan., Hazama S; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan., Tokumitsu Y; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan., Shindo Y; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan., Matsui H; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan., Matsukuma S; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan., Nakagami Y; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan., Tamada K; Department of Immunology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan., Udaka K; Department of Immunology, Kochi Medical School, Nankoku, Kochi, Japan., Sakamoto M; Department of Pathology, Keio University School of Medicine, Shinjuku, Tokyo, Japan., Saito A; Department of AI Applied Quantitative Clinical Science, Tokyo Medical University, Shinjuku, Tokyo, Japan., Kouki Y; Department of Pharmacy, Yamaguchi University Hospital, Ube, Yamaguchi, Japan., Uematsu T; Department of Pharmacy, Yamaguchi University Hospital, Ube, Yamaguchi, Japan., Xu M; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan., Iida M; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan., Tsunedomi R; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan., Suzuki N; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan., Takeda S; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan., Ioka T; Oncology Center, Yamaguchi University Hospital, Ube, Yamaguchi, Japan., Doi S; CYTLIMIC Inc, Shinagawa, Tokyo, Japan., Nagano H; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan.

Publikováno v: Hepatology research : the official journal of the Japan Society of Hepatology [Hepatol Res] 2023 Jul; Vol. 53 (7), pp. 649-660. Date of Electronic Publication: 2023 Mar 30.

Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL.

Autor: Yagishita S; Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan., Goto Y; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan., Nishio M; Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Akamatsu H; Internal Medicine III, Wakayama Medical University, Wakayama, Japan., Hayashi H; Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan., Miura S; Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan., Tamada K; Department of Immunology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan., Kagamu H; Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan., Hamada A; Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan., Ohuchi M; Department of Pharmacology and Therapeutics, Fundamental Innovative Oncology Core, National Cancer Center Research Institute, Tokyo, Japan., Gemma A; Department of Pulmonary Medicine and Oncology, Nippon Medical School, Graduate School of Medicine, Tokyo, Japan., Yoshino I; Department of General Thoracic Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.; Department of Thoracic Surgery, International University of Health and Welfare Narita Hospital, Narita, Japan., Misumi T; Department of Biostatistics, Yokohama City University School of Medicine, Kanagawa, Japan.; Department of Data Science, National Cancer Center Hospital East, Chiba, Japan., Hata A; Department of Thoracic Oncology, Kobe Minimally Invasive Cancer Center, Hyogo, Japan., Hara S; Department of Respiratory Medicine, Itami City Hospital, Hyogo, Japan., Kijima T; Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Hyogo, Japan., Masaki F; Department of Respiratory Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan., Iwasawa S; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan., Nakagawa S; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan., Tatsuno M; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan., Mitsudomi T; Kindai Hospital Global Research Alliance Center and Thoracic Surgery, Kindai University, Osaka, Japan.

Publikováno v: JTO clinical and research reports [JTO Clin Res Rep] 2024 May 16; Vol. 5 (7), pp. 100683. Date of Electronic Publication: 2024 May 16 (Print Publication: 2024).

Intracranial mycotic aneurysm rupture following cupping therapy.

Autor: Dai M; Department of Cerebrovascular Surgery, International Medical Center, Saitama Medical University, Hidaka, Japan., Suzuki K; Department of Cerebrovascular Surgery, International Medical Center, Saitama Medical University, Hidaka, Japan., Sato H; Department of Cerebrovascular Surgery, International Medical Center, Saitama Medical University, Hidaka, Japan., Tabata S; Department of Cerebrovascular Surgery, International Medical Center, Saitama Medical University, Hidaka, Japan., Kume H; Department of Cerebrovascular Surgery, International Medical Center, Saitama Medical University, Hidaka, Japan., Nishikata M; Department of Cerebrovascular Surgery, International Medical Center, Saitama Medical University, Hidaka, Japan., Tamada K; Department of Cerebrovascular Surgery, International Medical Center, Saitama Medical University, Hidaka, Japan., Ooigawa H; Department of Cerebrovascular Surgery, International Medical Center, Saitama Medical University, Hidaka, Japan., Kurita H; Department of Cerebrovascular Surgery, International Medical Center, Saitama Medical University, Hidaka, Japan.

Publikováno v: Surgical neurology international [Surg Neurol Int] 2024 Apr 05; Vol. 15, pp. 119. Date of Electronic Publication: 2024 Apr 05 (Print Publication: 2024).